Is Mounjaro available on the NHS for weight loss — and what are your options?

You meet the BMI number, but NHS access still depends on timing

Picture this: your GP tells you your BMI is 42, you have sleep apnoea, high blood pressure and type 2 diabetes, and you've read that Mounjaro is now recommended by NICE. You expect a prescription at your next appointment. Then your GP explains there are waiting lists, criteria lists, and cohort rollout dates you hadn't heard of. That gap between expectation and reality is where most people currently sit.

NICE published its recommendation for tirzepatide (TA1026) in December 2024 and updated it in September 2025. It recommended Mounjaro for adults with a BMI of 35 or above and at least one qualifying condition, lower thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under that guidance. But NICE recommendations and NHS availability are not the same thing, and if you want to understand how NHS Mounjaro weight loss access actually works in practice, the phased rollout detail explains why eligibility on paper and eligibility in reality can look very different. NHS England is phasing rollout in steps to manage demand and capacity.

The five qualifying conditions are: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. From June 2025, the NHS opened access to people with a BMI of 40 or above and four or more of those five conditions. A second cohort, covering BMI 35–39.9 with four or more of the same conditions, activated in June 2026. Further cohorts extending access to people with three qualifying conditions are planned from around March 2027. Participation varies by GP practice, not every surgery has opted in, and those that have are subject to local capacity constraints.

If you're wondering whether Mounjaro is available on the NHS for your situation, we've laid out the phasing detail clearly so you can see exactly where the current thresholds sit.

What happens if the NHS route isn't open to you yet

If your BMI is 33, or you have two qualifying conditions rather than four, or your GP practice hasn't yet joined the rollout, the NHS route is closed to you for now. That's a straightforward factual situation, not a judgement on whether treatment would help you.

The lawful alternative is a private prescription from a GPhC-registered pharmacy following a clinical assessment. The licensed eligibility criteria for private prescribing are broader than the NHS cohort thresholds: adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition, may be clinically suitable. A prescriber still reviews every application individually, BMI alone doesn't decide anything.

At nume, a GPhC-registered Independent Prescriber reads your consultation answers the same day, a real clinician, not a decision algorithm. If treatment is clinically suitable, the pen is dispatched the same day for free next-working-day delivery via DPD, in plain packaging. Your first pen will live in the fridge when it arrives; the storage section of your patient leaflet tells you the exact handling window.

If you'd like to understand the cost side of private treatment, our Mounjaro cost page explains what legitimate pricing includes and the market context around it, without pressure.

The process through a private pharmacy, step by step

Getting Mounjaro privately through a regulated pharmacy involves fewer steps than many people expect. You complete a free online consultation, no GP referral, no waiting list. A prescriber reviews the full picture, including your weight, medical history and any current medicines. NHS England's guidance on weight-management injections sets out what clinical wraparound matters alongside any GLP-1 treatment, and that informs how our prescribers approach ongoing review too.

Identity and weight are verified, nume doesn't offer treatment on the basis of self-reported figures alone. If approved, treatment is dispensed from our GPhC-registered pharmacy (registration number 9012878, verifiable on the GPhC register) and delivered to your door. Before every repeat order, a clinician re-reviews your case. There are no subscriptions and no auto-renewals.

For people weighing up the NHS and private routes in more depth, this page walks through the eligibility comparison in detail. And if you're unsure whether Mounjaro or another licensed weight-loss treatment is more likely to suit you, our treatment overview explains what's available.

Tirzepatide is a Black Triangle medicine, meaning the MHRA collects additional safety data on it. It's not suitable for everyone, people who are pregnant, breastfeeding or trying to conceive should not use it, and under-18s are outside the licensed age range. A prescriber will flag any contraindications during your consultation.

A note on checking whether your pharmacy is legitimate

Mounjaro is a prescription-only medicine. It cannot lawfully be supplied without a valid prescription following a clinical assessment, and the MHRA has warned publicly about fake pens sold through social media and unverified online sellers. If you're asking whether you can buy Mounjaro from a chemist, the answer depends on whether that pharmacy is GPhC-registered and has a prescriber in place to carry out a proper clinical assessment first. Red flags include sellers offering Mounjaro without a prescription, prices well below the market, or "discount codes" for medicines from sources you can't verify.

If you're ready to find out whether you're clinically suitable for treatment, start your free consultation with our prescribing team. No commitment, no upfront payment, and the clinical review happens the same day. We also offer the option to buy Mounjaro with Klarna, so you can spread the cost of treatment if that makes it easier to get started.